Terms: = Bone cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Treatment
426 results:
1. Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
[TBL] [Abstract] [Full Text] [Related]
2. Lapatinib antitumor effect is associated with pi3k and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
3. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic Prostate cancer.
Uzelac M; Xin R; Ongkeko WM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
[TBL] [Abstract] [Full Text] [Related]
4. USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the pi3k/AKT signaling pathway.
Li A; Wang S; Nie J; Xiao S; Xie X; Zhang Y; Tong W; Yao G; Liu N; Dan F; Shu Z; Liu J; Liu Z; Yang F
Cell Death Dis; 2024 Mar; 15(3):235. PubMed ID: 38531846
[TBL] [Abstract] [Full Text] [Related]
5. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (pi3k)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
6. Hydroxychloroquine interaction with phosphoinositide 3-kinase modulates prostate cancer growth in bone microenvironment: In vitro and molecular dynamics based approach.
Abdullah KM; Sharma G; Qais FA; Khan I; Takkar S; Kaushal JB; Kanchan RK; Sarwar T; Chakravarti B; Siddiqui JA
Int J Biol Macromol; 2024 May; 266(Pt 1):130912. PubMed ID: 38513896
[TBL] [Abstract] [Full Text] [Related]
7. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract] [Full Text] [Related]
8. Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology and
Pang H; Wu H; Zhan Z; Wu T; Xiang M; Wang Z; Song L; Wei B
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186298
[TBL] [Abstract] [Full Text] [Related]
9. Solute carrier family 35 member A2 regulates mitophagy through the pi3k/AKT/mTOR axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.
Luo X; Zhang J; Guo C; Jiang N; Zhang F; Jiao Q; Xu K; Yang J; Qu G; Lv XB; Zhang Z
Gene; 2024 Mar; 898():148110. PubMed ID: 38151177
[TBL] [Abstract] [Full Text] [Related]
10. Caulis Spatholobi extracts inhibit osteosarcoma growth and metastasis through suppression of CXCR4/pi3k/AKT signaling.
Jiang Y; Gao Y; Li X; He F; Liu Y; Wang R
J Orthop Surg Res; 2023 Dec; 18(1):985. PubMed ID: 38129870
[TBL] [Abstract] [Full Text] [Related]
11. Exploration in the Mechanism of Ginsenoside Rg5 for the treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.
Liu MY; Jiang DX; Zhao X; Zhang L; Zhang Y; Liu ZD; Liu RZ; Li HJ; Rong XY; Gao YZ
Orthop Surg; 2024 Feb; 16(2):462-470. PubMed ID: 38086608
[TBL] [Abstract] [Full Text] [Related]
12. Indirect treatment Comparisons of Mosunetuzumab With Third- and Later-Line treatments for Relapsed/Refractory Follicular Lymphoma.
Bosch F; Kuruvilla J; Vassilakopoulos TP; Maio DD; Wei MC; Zumofen MB; Nastoupil LJ
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):105-121. PubMed ID: 37981564
[TBL] [Abstract] [Full Text] [Related]
13. Blue light photobiomodulation induced apoptosis by increasing ROS level and regulating SOCS3 and PTEN/pi3k/AKT pathway in osteosarcoma cells.
Yang J; Jiang H; Fu Q; Qin H; Li Y; Liu M
J Photochem Photobiol B; 2023 Dec; 249():112814. PubMed ID: 37956614
[TBL] [Abstract] [Full Text] [Related]
14. Amino-Functionalized Zirconium-Based Metal-Organic Frameworks as Bifunctional Nanomaterials to Treat bone Tumors and Promote Osteogenesis.
Yuan J; Zeng Y; Pan Z; Feng Z; Bao Y; Ye Z; Li Y; Tang J; Liu X; He Y
ACS Appl Mater Interfaces; 2023 Nov; 15(46):53217-53227. PubMed ID: 37943099
[TBL] [Abstract] [Full Text] [Related]
15. n-3 PUFAs Show Promise as Adjuvants in Chemotherapy, Enhancing their Efficacy while Safeguarding Hematopoiesis and Promoting bone Generation.
Gurav P; Garad S; Nirmala KR
Curr Top Med Chem; 2024; 24(1):45-59. PubMed ID: 37907485
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
17. Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
Hill BT; Ma S; Zent CS; Baran AM; Wallace DS; Advani A; Winter A; Winter J; Gordan L; Karmali R; Liesveld JL; Mulford DA; Rowland C; Bui A; Sportelli P; Miskin HP; Weiss MS; Friedberg JW; Barr PM
Blood Adv; 2024 Jan; 8(2):378-387. PubMed ID: 37871300
[TBL] [Abstract] [Full Text] [Related]
18. The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf CL; Pruett C; Lighter D; Jorcyk CL
Front Immunol; 2023; 14():1239732. PubMed ID: 37841259
[TBL] [Abstract] [Full Text] [Related]
19. Synthesis and application of small molecules approved for the treatment of lymphoma.
Guo YY; Zhang JY; Sun JF; Nie P; Gao H
Eur J Med Chem; 2023 Dec; 261():115835. PubMed ID: 37801827
[TBL] [Abstract] [Full Text] [Related]
20. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the pi3k/AKT/mTOR pathway.
Wei Z; Xia K; Zheng D; Gong C; Guo W
Mol Med; 2023 Oct; 29(1):133. PubMed ID: 37789274
[TBL] [Abstract] [Full Text] [Related]
[Next]
